FDA granted RMAT and Fast Track designations to Lyell Immunopharma.
3 reports, 1 independent
Updated Sep 3
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted RMAT and Fast Track designations to Lyell Immunopharma.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- LYL314, a next-generation CAR T-cell therapy, was identified as a product of Lyell Immunopharma.Sub-event
Lyell Immunopharma received RMAT and Fast Track designations from the FDA.1 source
- LYL314 received designations and presented clinical data at a conference in Lugano.
Keep exploring
The entities involved
-
Lyell Immunopharma (United States)
company in South San Francisco, United States
Nothing else this week.
- FDA
Coverage
Newest first; wire copies grouped- GlobeNewswireLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee PiNACLE - H2H wi
- GlobeNewswireLyell Immunopharma Announces Participation in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharm
- Unknown outlet